Registration will open September 1, 2016
Abstract submission will open September 1, 2016
Exhibitor & Support Opportunities
Act now to identify the best strategies at TAT 2017 to get the RESULTS your company expects in this dynamic marketplace.
Phase 1: the revolution is ongoing!
A revolution is ongoing, which has already changed and will continue to change the role of phase 1 studies in oncology drug development.
TAT 2016 report
A brief report of TAT 2016 is online now. Over the three days of the conference, 45 oral presentations covered 23 unique new drugs or drug classes in early-phase clinical trials at the time of the conference.